Metastatic Nasopharyngeal Carcinoma Clinical Trials

15 clinical trials for Metastatic Nasopharyngeal Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer — RECRUITING · PHASE2
• EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma — RECRUITING · PHASE1
• Metastatic Nasopharyngeal Carcinoma — RECRUITING · PHASE1
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study — NOT_YET_RECRUITING · PHASE2
• Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer — SUSPENDED · PHASE2
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer — TERMINATED · PHASE3
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma — NOT_YET_RECRUITING · PHASE2
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure — OTHER · PHASE2
• Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study — OTHER · PHASE2
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. — OTHER · PHASE2
• Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment — NOT_YET_RECRUITING · PHASE2
• A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma — OTHER · PHASE2
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer — WITHDRAWN · PHASE2
• Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) — COMPLETED · PHASE2
• Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma — OTHER · PHASE1

Refine this search